|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Schering-Plough_Corporation
|
|
gptkbp:awards
|
various industry awards
|
|
gptkbp:business_model
|
manufacturing
marketing and sales
pharmaceutical research and development
|
|
gptkbp:ceo
|
gptkb:Robert_M._Davis
|
|
gptkbp:clinical_trial
|
ongoing
rare diseases
chronic diseases
vaccine development
global health
cancer therapies
|
|
gptkbp:collaborations
|
government agencies
academic institutions
biotech companies
|
|
gptkbp:community_programs
|
gptkb:healthcare_access
mental health support
health education
disaster relief
disease prevention
|
|
gptkbp:conducts_research_on
|
gptkb:Dr._Julie_Gerberding
|
|
gptkbp:employees
|
over 70,000
|
|
gptkbp:founded
|
1891
|
|
gptkbp:global_presence
|
over 140 countries
|
|
gptkbp:headquarters
|
gptkb:Kenilworth
gptkb:United_States
gptkb:Kenilworth,_New_Jersey
|
|
gptkbp:history
|
established in 1891 as a subsidiary of Merck & Co.
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Merck Sharp & Dohme Corp.
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:market
|
global market
|
|
gptkbp:notable_products
|
gptkb:Januvia
gptkb:Zetia
gptkb:Gardasil
gptkb:Keytruda
gptkb:Singulair
|
|
gptkbp:parent_company
|
gptkb:Merck_&_Co.,_Inc.
|
|
gptkbp:partnerships
|
various healthcare organizations
|
|
gptkbp:philanthropy
|
gptkb:Merck_Foundation
|
|
gptkbp:products
|
antibiotics
vaccines
oncology drugs
diabetes medications
|
|
gptkbp:research_and_development
|
biopharmaceuticals
|
|
gptkbp:research_focus
|
gptkb:diabetes
neurology
oncology
cardiovascular diseases
infectious diseases
immunology
|
|
gptkbp:revenue
|
$48 billion (2020)
|
|
gptkbp:stock_symbol
|
MRK
|
|
gptkbp:subsidiary
|
gptkb:Merck_&_Co.
|
|
gptkbp:sustainability_initiatives
|
community engagement
environmental responsibility
access to medicines
|
|
gptkbp:website
|
www.msd.com
|
|
gptkbp:bfsParent
|
gptkb:Merck_Sharp_&_Dohme
|
|
gptkbp:bfsLayer
|
5
|